))
Deep Dive 177 – Patents and Pandemics: Innovation Policy and the Patent Waiver Petition at the WTO
Manage episode 314171204 series 3276400
Innehåll tillhandahållet av The Federalist Society. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av The Federalist Society eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
India and South Africa have submitted a petition to the World Trade Organization seeking a waiver of all intellectual property rights under international treaties on drugs, vaccines, or other responses to the COVID-19 pandemic. This waiver petition has provoked an intense policy debate over the role of intellectual property in healthcare innovation.
On the one hand, advocates for the waiver argue that patents have been a blockade for patient access and created higher prices, especially in developing countries. On the other hand, opponents of the waiver maintain that there is no evidence that patents are blocking drug development or distribution for the COVID-19 pandemic. The opponents also maintain that patents made possible over the past several decades the R&D investments, the creation of technical know-how, and the commercial agreements that have been the launching pad for the unprecedented development of several vaccines and other medical treatments in less than a year.
This live podcast features experts in innovation policy on both sides of the issue debating the role of patents in medical care and how the United States should respond to the waiver petition.
Featuring:
- Richard Blaylock, Partner, Pillsbury Winthrop Shaw Pittman LLP
- Brian O'Shaughnessy, Partner, Dinsmore & Shohl LLP and Past President, Licensing Executives Society, USA & Canada
- Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Industry Organization
- [Moderator] Paul R. Michel, Chief Judge (ret.), U.S. Court of Appeals for the Federal Circuit
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
…
continue reading
On the one hand, advocates for the waiver argue that patents have been a blockade for patient access and created higher prices, especially in developing countries. On the other hand, opponents of the waiver maintain that there is no evidence that patents are blocking drug development or distribution for the COVID-19 pandemic. The opponents also maintain that patents made possible over the past several decades the R&D investments, the creation of technical know-how, and the commercial agreements that have been the launching pad for the unprecedented development of several vaccines and other medical treatments in less than a year.
This live podcast features experts in innovation policy on both sides of the issue debating the role of patents in medical care and how the United States should respond to the waiver petition.
Featuring:
- Richard Blaylock, Partner, Pillsbury Winthrop Shaw Pittman LLP
- Brian O'Shaughnessy, Partner, Dinsmore & Shohl LLP and Past President, Licensing Executives Society, USA & Canada
- Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Industry Organization
- [Moderator] Paul R. Michel, Chief Judge (ret.), U.S. Court of Appeals for the Federal Circuit
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
374 episoder
Dela
